Well-managed warfarin still useful for stroke prevention
A study of 40,000 patients with atrial fibrillation suggests that warfarin is a valid treatment for stroke prevention.
Studies of patients with atrial fibrillation (AF) have shown that non-vitamin K oral anticoagulants carry a lower risk of intracranial bleeding than warfarin. But the mean time in therapeutic range (TTR) in these studies was below 70%, suggesting suboptimal warfarin management.
Researchers from Sweden conducted a retrospective cohort study using data on 40,449 AF patients treated with warfarin over a six-year period to assess the relationship between warfarin management and complications.
They found that patients with an individual TTR above 70% had a significantly lower incidence of treatment complications. For example, in these patients, the rate of major bleeding was 1.61% compared with 3.81% among those with a lower individual TTR.
Reporting in JAMA Cardiology (online, 20 April 2016), the team say the findings suggest that well-managed warfarin treatment remains a valid alternative in patients with AF who require stroke prevention therapy.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20201087
Recommended from Pharmaceutical Press